Strategic Expansion Quantum Surgical is expanding presence with offices in Montpellier and Miami and recent partnerships and acquisitions including NeuWave Medical acquisition in 2026 and a Taiwan collaboration in 2025, signaling opportunities to align sales efforts across multiple regions and healthcare markets.

Clinical Partnerships Active collaborations with leading institutions (Paoli-Calmettes Institute) and a partnership framework with Rush University Medical Center, plus ongoing clinical studies, create entry points for hospital systems and oncology centers to adopt Epione robotic ablation and related AI-driven precision therapies.

Adoption Momentum Wide adoption footprint with hundreds of patients treated and recognition from industry awards (Innovation Prize 2024, JFR Innovation Award 2023) supports the case for scale sales, including service contracts, training programs, and deployment of additional robotic systems.

Financing & Accessibility Recent €30 million EIB loan backed by InvestEU and a growing revenue range indicate improving financial health and funding readiness for hospitals to invest in robotic oncology platforms, offering financing conversations alongside equipment sales.

Competitive Positioning As a specialized French medical robotics and AI player with a targeted cancer ablation platform, Quantum Surgical can position against larger incumbents by emphasizing standardization of access, minimally invasive treatment benefits, and cross-border care delivery to oncology networks and radiology departments.